Biological Assembly 1  

 3D View: Structure | Electron Density | Ligand Interaction

Standalone Viewers  
Protein Workshop | Ligand Explorer

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A 

Biological assembly 1 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 110411.84 
• Atom Count: 6847 
• Residue Count: 960 
• Unique protein chains: 1

3DBS

Structure of PI3K gamma in complex with GDC0941

• DOI: 10.2210/pdb3DBS/pdb

• Classification: TRANSFERASE
• Organism(s): Homo sapiens


• Deposited: 2008-06-02 Released: 2008-06-17 
• Deposition Author(s): Wiesmann, C., Ultsch, M.

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.8 Å
• R-Value Free: 0.262 
• R-Value Work: 0.219 

Literature

The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer

Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, S., Baker, S.J., Box, G., Chuckowree, I.S., Clarke, P.A., Depledge, P., Eccles, S.A., Friedman, L.S., Hayes, A., Hancox, T.C., Kugendradas, A., Lensun, L., Moore, P., Olivero, A.G., Pang, J., Patel, S., Pergl-Wilson, G.H., Raynaud, F.I., Robson, A., Saghir, N., Salphati, L., Sohal, S., Ultsch, M.H., Valenti, M., Wallweber, H.J.A., Wan, N.C., Wiesmann, C., Workman, P., Zhyvoloup, A., Zvelebil, M.J., Shuttleworth, S.J.

(2008) J.Med.Chem. 51: 5522-5532

• PubMed: 18754654 
• DOI: 10.1021/jm800295d


• PubMed Abstract: 
  

Phosphatidylinositol-3-kinase (PI3K) is an important target in cancer due to the deregulation of the PI3K/ Akt signaling pathway in a wide variety of tumors. A series of thieno[3,2-d]pyrimidine derivatives were prepared and evaluated as inhibitors of PI3 kinase p110alpha. The synthesis, biological activity, and further profiling of these compounds are described. This work resulted in the discovery of 17, GDC-0941, which is a potent, selective, orally bioavailable inhibitor of PI3K and is currently being evaluated in human clinical trials for the treatment of cancer.

---

Organizational Affiliation: 

Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom. [e-mail]

Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details
Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma isoform	A	960	Homo sapiens	Mutation(s): 0  Gene Names: PIK3CG EC: 2.7.1.153
Find proteins for P48736 (Homo sapiens) Go to Gene View: PIK3CG Go to UniProtKB:  P48736

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram & Interactions
GD9	A	2-(1H-indazol-4-yl)-6-{[4-(methylsulfonyl)piperazin-1-yl]methyl}-4-morpholin-4-yl-thieno[3,2-d]pyrimidine C23 H27 N7 O3 S2 LHNIIDJUOCFXAP-UHFFFAOYSA-N

External Ligand Annotations
ID	Binding Affinity (Sequence Identity %)
GD9	IC50: 42 - 298 nM (100) BINDINGDB
GD9	Kd: 48 nM (100) BINDINGDB
GD9	Ki: 1.4 - 41.8 nM (100) BINDINGDB
GD9	IC50: 75 nM PDBBIND

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.8 Å
• R-Value Free: 0.262 
• R-Value Work: 0.219 
• Space Group: C 1 2 1

Unit Cell:

Length (Å)	Angle (°)
a = 144.284	α = 90.00
b = 67.762	β = 95.31
c = 106.972	γ = 90.00

Software Package:

Software Name	Purpose
REFMAC	refinement
HKL-2000	data collection
AMoRE	phasing
HKL-2000	data reduction
HKL-2000	data scaling

Structure Validation

Entry History 

Deposition Data

• Deposited Date: 2008-06-02 
• Released Date: 2008-06-17 
• Deposition Author(s): Wiesmann, C., Ultsch, M.

Revision History 

• Version 1.0: 2008-06-17
  Type: Initial release
• Version 1.1: 2011-07-13
  Type: Advisory, Version format compliance